In the last trading session, 0.88 million Eagle Pharmaceuticals Inc (NASDAQ:EGRX) shares changed hands as the company’s beta touched 0.51. With the company’s per share price at $2.45 changed hands at -$1.11 or -31.18% during last session, the market valuation stood at $31.83M. EGRX’s last price was a discount, traded about -540.41% off its 52-week high of $15.69. The share price had its 52-week low at $3.21, which suggests the last value was -31.02% down since then. When we look at Eagle Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.1 million shares, with the 3-month average coming to 105.08K.
Eagle Pharmaceuticals Inc (NASDAQ:EGRX) trade information
Instantly EGRX was in red as seen at the end of in last trading. With action -36.86%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -53.15%, with the 5-day performance at -36.86% in the red. However, in the 30-day time frame, Eagle Pharmaceuticals Inc (NASDAQ:EGRX) is -47.42% down. Looking at the short shares, we see there were 0.35 million shares sold at short interest cover period of 3.91 days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Eagle Pharmaceuticals Inc (EGRX) estimates and forecasts
Year-over-year growth is forecast to reach -18.40% down from the last financial year.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of 62.83M. 1 analysts are of the opinion that Eagle Pharmaceuticals Inc’s revenue for the current quarter will be 64.51M. The company’s revenue for the corresponding quarters a year ago was 62.08M and 60.7M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 1.20%. The estimates for the next quarter sales put growth at 6.30%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -3.56%.
EGRX Dividends
Eagle Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2023-Aug-08.
Eagle Pharmaceuticals Inc (NASDAQ:EGRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 12.02% of Eagle Pharmaceuticals Inc shares while 76.66% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 87.13%. There are 76.66% institutions holding the Eagle Pharmaceuticals Inc stock share, with NANTAHALA CAPITAL MANAGEMENT, LLC the top institutional holder. As of 2024-06-30, the company held 14.9881% of the shares, roughly 1.96 million EGRX shares worth $10.99 million.
AIGH CAPITAL MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 9.2546% or 1.21 million shares worth $6.78 million as of 2024-06-30.
